Inari Medical (NARI) reported a Q3 net loss late Monday of $0.31 per diluted share, compared with net income of $0.05 a year earlier.
Analysts polled by Capital IQ expected a $0.18 loss.
Revenue in the three months ended Sept. 30 rose to $153.4 million from $126.4 million a year earlier.
Analysts surveyed by Capital IQ expected $150.7 million.
In 2024, the medical device company expects revenue of $601.5 million to $604.5 million versus the previous outlook of $594.5 million to $604.5 million.
Analysts project $600 million.
Inari said it continues to expect to reach sustained operating profitability in H1.
The company's shares rose 10% in after-hours activity.
Price: 47.00, Change: +4.44, Percent Change: +10.43
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。